We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| NovoCure Ltd | NASDAQ:NVCR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.32 | 2.62% | 12.55 | 12.50 | 12.65 | 12.65 | 12.01 | 12.15 | 762,109 | 01:00:00 |
From Apr 2019 to Apr 2024
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Novocure Limited. (“Novocure” or the “Company”) (Nasdaq: NVCR) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Novocure shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
Novocure creates and markets treatment for solid tumor cancers therapy called the tumor treating fields (“TTFields”). Novocure advertises its proprietary therapy, TTFields delivery system, through the Optune name as a monotherapy treatment for adult patients with glioblastoma brain cancer.
Novocure revealed that its new Optune prescriptions dropped to 657 in the second quarter from 755 in the first. Asaf Danziger, Chief Executive Officer of Novocure, stated, “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
When this information was disclosed to the public, Novocure’s stock fell over 29%, causing investors serious harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161222005221/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq., 800-977-7401Brian Schall, Esq., 800-977-7401info@goldberglawpc.comhttp://www.Goldberglawpc.com
1 Year NovoCure Chart |
1 Month NovoCure Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
